Examples of using Repeat-dose in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Repeat-dose toxicology studies identified the liver and bone marrow as target organs in the dog.
Depletion of lymphoid organs was observed in repeat-dose toxicity studies in rats and cynomolgus monkeys.
Repeat-dose toxicity studies in rat and dog showed mainly dose-limiting pharmacological effects, such as sedation.
Hyper-/hypoplastic changes of the chondrocytes in the physis were noted in repeat-dose toxicity studies in rats.
Effects observed in the repeat-dose toxicity studies were due to the exaggerated pharmacodynamic effect of dabigatran.
Including range-finding studies that cannot appropriately be included under repeat-dose toxicity or pharmacokinetics.
Iclusig has been evaluated in safety pharmacology, repeat-dose toxicity, genotoxicity, reproductive toxicity, phototoxicity and carcinogenicity studies.
Short- or medium-term studies including range-findingstudies that cannot appropriately be included under repeat-dose toxicity or pharmacokinetics.
Caecal lesions observed in some repeat-dose studies with rats, but not in monkeys, are not relevant for humans under normal conditions of administration.
However reversible hypospermia and testicular vacuolation andimmaturity of the ovaries were observed in a repeat-dose toxicity study with fenofibric acid in young dogs.
In repeat-dose studies the effects seen after trametinib exposure are found mainly in the skin, gastrointestinal tract, haematological system, bone and liver.
Renal function status had no effect on the clearance orexposure of carfilzomib following single or repeat-dose administration at doses up to 20 mg/m2 see section 4.2.
In a long-term dog repeat-dose study, high serum prolactin levels were associated with effects on male and female reproductive tissues.
Dinutuximab(or the murine monoclonal antibody 14.18) has been administered tomice, rabbits, rats, and dogs in single- or repeat-dose regimens that exceed the dose that is used clinically.
Other liver-related changes in repeat-dose toxicity studies in rats and dogs included increased serum aminotransferases, subacute inflammation(rats only), and single-cell necrosis.
Sufentanil has been shown to induce opioid-like effects in a variety of laboratory animals(dogs, rats, guinea pigs, hamsters)at doses above those inducing analgesia and in two repeat-dose studies with sufentanil sublingual tablets administered buccally in Golden Syrian hamster.
Effects observed in repeat-dose toxicity studies were mainly due to the exaggerated pharmacodynamic activity of riociguat haemodynamic and smooth muscle relaxing effects.
Testicular changes(seminiferous tubular degeneration) were evident in repeat-dose toxicology studies in rodents and dogs at exposures≥ 26 times those in humans.
In repeat-dose studies in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable to that observed in adult animals, and there was no evidence of neurotoxicity or adverse reactions on development.
No effects on male or female fertility and reproductive performance indices were observed at≤100 mg/kg/day yielding exposures approximately 8 times those obtained with the maximum recommended human dose of the ivacaftor component of Orkambi based on summed AUCs of ivacaftor and its metabolites extrapolated from Day90 exposures at 100 mg/kg/day in the 6-month repeat-dose toxicity study in this species.
High serum prolactin levels in long-term repeat-dose studies in female rats were associated with effects on bones, adrenal glands, and reproductive tissues.
The repeat-dose toxicology studies conducted in young cynomolgus monkeys at doses of 9.2 and 46 mg/kg/week(up to 22-fold greater exposure than in patients receiving 11 mg/kg every 3 weeks) with siltuximab showed no signs indicative of toxicity.
Trametinib may impair female fertility in humans, as in repeat-dose studies, increases in cystic follicles and decreases in corpora lutea were observed in female rats at exposures below the human clinical exposure based on AUC.
However, in repeat-dose toxicity studies, no histopathological findings were noted on reproductive organs in males and females in rats and dogs at doses up to 450 mg/kg/day at exposures below the anticipated clinical exposure based on AUC comparison.
The plasma amprenavirpharmacokinetics were evaluated in a 14 day repeat-dose study in HIV-1 infected adult subjects with mild, moderate, or severe hepatic impairment receiving fosamprenavir with ritonavir compared to matched control subjects with normal hepatic function.
In repeat-dose studies in rats and dogs(once per day without light for up to 4 weeks), mild extravascular haemolysis and haematopoietic responses were seen with exposure greater than approximately 70 times(rats) and 32 times(dogs) the exposure(based on AUC) of the recommended human dose.
Adverse reactions not observed in clinical studies,but seen in rats during repeat-dose toxicity studies at exposure levels higher than clinical exposure levels and with possible relevance to clinical use were eye disorders characterized by subcapsular lens fiber swelling/degeneration.
Non-clinical repeat-dose toxicity and safety pharmacology studies in rats revealed no special hazard for humans, except a slight but significant saluretic effect at doses below the recommended dose for ALL/LBL patients.
This finding was not observed in repeat-dose studies in other species, including monkeys administered entecavir daily for 1 year at exposures≥ 100 times those in humans.
Repeat-dose toxicity studies in rats, dogs and monkeys produced changes typically associated with administration of an anti-cancer medicinal product eliciting cytotoxic effects on populations of rapidly dividing cells, such as anaemia, decrease in the immune and digestive system function, disruption of spermatogenesis, and atrophy in male and female reproductive organs.